| Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar H Chemaitelly, P Tang, MR Hasan, S AlMukdad, HM Yassine, ... New England Journal of Medicine 385 (24), e83, 2021 | 877 | 2021 |
| Effects of previous infection and vaccination on symptomatic omicron infections HN Altarawneh, H Chemaitelly, HH Ayoub, P Tang, MR Hasan, ... New England Journal of Medicine 387 (1), 21-34, 2022 | 479 | 2022 |
| BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar P Tang, MR Hasan, H Chemaitelly, HM Yassine, FM Benslimane, ... Nature medicine 27 (12), 2136-2143, 2021 | 460 | 2021 |
| Protection against the Omicron variant from previous SARS-CoV-2 infection HN Altarawneh, H Chemaitelly, MR Hasan, HH Ayoub, S Qassim, ... New England Journal of Medicine 386 (13), 1288-1290, 2022 | 413 | 2022 |
| mRNA-1273 COVID-19 vaccine effectiveness against the B. 1.1. 7 and B. 1.351 variants and severe COVID-19 disease in Qatar H Chemaitelly, HM Yassine, FM Benslimane, HA Al Khatib, P Tang, ... Nature medicine 27 (9), 1614-1621, 2021 | 404 | 2021 |
| Effect of mRNA vaccine boosters against SARS-CoV-2 Omicron infection in Qatar LJ Abu-Raddad, H Chemaitelly, HH Ayoub, S AlMukdad, HM Yassine, ... New England Journal of Medicine 386 (19), 1804-1816, 2022 | 372 | 2022 |
| Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA. 1 and BA. 2 subvariants in Qatar H Chemaitelly, HH Ayoub, S AlMukdad, P Coyle, P Tang, HM Yassine, ... Nature communications 13 (1), 3082, 2022 | 224 | 2022 |
| Association of prior SARS-CoV-2 infection with risk of breakthrough infection following mRNA vaccination in Qatar LJ Abu-Raddad, H Chemaitelly, HH Ayoub, HM Yassine, FM Benslimane, ... Jama 326 (19), 1930-1939, 2021 | 158 | 2021 |
| Coronavirus disease 2019 disease severity in children infected with the omicron variant AA Butt, SR Dargham, S Loka, RM Shaik, H Chemaitelly, P Tang, ... Clinical Infectious Diseases 75 (1), e361-e367, 2022 | 142 | 2022 |
| Protective effect of previous SARS-CoV-2 infection against Omicron BA. 4 and BA. 5 subvariants HN Altarawneh, H Chemaitelly, HH Ayoub, MR Hasan, P Coyle, ... New England Journal of Medicine 387 (17), 1620-1622, 2022 | 116 | 2022 |
| Duration of immune protection of SARS-CoV-2 natural infection against reinfection H Chemaitelly, N Nagelkerke, HH Ayoub, P Coyle, P Tang, HM Yassine, ... Journal of Travel Medicine 29 (8), taac109, 2022 | 94 | 2022 |
| Waning mRNA-1273 vaccine effectiveness against SARS-CoV-2 infection in Qatar LJ Abu-Raddad, H Chemaitelly, R Bertollini New England Journal of Medicine 386 (11), 1091-1093, 2022 | 93 | 2022 |
| Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses LJ Abu-Raddad, H Chemaitelly, HM Yassine, FM Benslimane, ... Journal of travel medicine 28 (7), taab083, 2021 | 88 | 2021 |
| Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage H Chemaitelly, HH Ayoub, P Coyle, P Tang, HM Yassine, HA Al-Khatib, ... Nature communications 13 (1), 4675, 2022 | 78 | 2022 |
| Within-host diversity of SARS-CoV-2 in COVID-19 patients with variable disease severities HA Al Khatib, FM Benslimane, IE Elbashir, PV Coyle, MA Al Maslamani, ... Frontiers in cellular and infection microbiology 10, 575613, 2020 | 76 | 2020 |
| Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study H Chemaitelly, HH Ayoub, S AlMukdad, P Coyle, P Tang, HM Yassine, ... The Lancet Microbe 3 (12), e944-e955, 2022 | 69 | 2022 |
| One year of SARS-CoV-2: genomic characterization of COVID-19 outbreak in Qatar FM Benslimane, HA Al Khatib, O Al-Jamal, D Albatesh, S Boughattas, ... Frontiers in cellular and infection microbiology 11, 768883, 2021 | 69 | 2021 |
| Immune imprinting and protection against repeat reinfection with SARS-CoV-2 H Chemaitelly, HH Ayoub, P Tang, MR Hasan, P Coyle, HM Yassine, ... New England Journal of Medicine 387 (18), 1716-1718, 2022 | 64 | 2022 |
| Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections LJ Abu-Raddad, H Chemaitelly, HH Ayoub, P Tang, P Coyle, MR Hasan, ... Nature communications 13 (1), 532, 2022 | 63 | 2022 |
| Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study H Chemaitelly, HH Ayoub, P Tang, P Coyle, HM Yassine, AA Al Thani, ... The Lancet Infectious Diseases 23 (7), 816-827, 2023 | 60 | 2023 |
